Elion Therapeutics

Recent Finacing

Series B

Recent Raise

$81M

Elion Therapeutics is a clinical-stage biotech developing SF001, a rationally designed polyene antifungal analog of amphotericin B, currently in multiple-ascending-dose trials for invasive fungal infections.

Founded 1955

Massachusetts, United States

11-50

Private

eliontx.com

Highlights

Focus Areas

Biotechnology

Pharmaceutical

Therapeutics

Recent Investors

Financials

$81M

Total Raised

1

Funding round

3

Investors

Team

Upgrade to view the team

See the team members at Elion Therapeutics.